Intervention not reported
Self‐controlled case series ‐ herpes ‐ herpes risk period (0 to 90 days) · children 9 months to 15 years old
The intervention showed no clear difference in self‐controlled case series ‐ herpes ‐ herpes risk period (0 to 90… (low certainty).
1 finding from 1 review
Intervention not reported
Self‐controlled case series ‐ pneumonia ‐ pneumonia risk period (0 to 90 days) · children 9 months to 15 years old
The intervention showed no clear difference in self‐controlled case series ‐ pneumonia ‐ pneumonia risk period (0… (low certainty).
1 finding from 1 review
Intervention not reported
Self‐controlled case series ‐ varicella zoster ‐ varicella zoster risk period (0 to 90 days) · children 9 months to 15 years old
The intervention showed no clear difference in self‐controlled case series ‐ varicella zoster ‐ varicella zoster… (low certainty).
1 finding from 1 review
Intervention not reported
Self‐controlled case series ‐ miscellaneous viral infections ‐ miscellaneous viral infections risk period (0 to 90 days) · children 9 months to 15 years old
The intervention showed no clear difference in self‐controlled case series ‐ miscellaneous viral infections ‐… (low certainty).
1 finding from 1 review
Intervention not reported
Case‐control: MMR (risk interval from 0 to 90 days) · children 9 months to 15 years old
The intervention showed no clear difference in case‐control: MMR (risk interval from 0 to 90 days) (low certainty).
1 finding from 1 review
Intervention not reported
Case‐control ‐ Jeryl Lynn ‐ risk interval 0 to 30 days · children 9 months to 15 years old
The intervention showed no clear difference in case‐control ‐ Jeryl Lynn ‐ risk interval 0 to 30 days (low certainty).
1 finding from 1 review
Intervention not reported
MMRV vs MMR+V ‐ by brand ‐ from 0 to 42 days after vaccination (Priorix‐Tetra) · children 9 months to 15 years old
The intervention showed no clear difference in MMRV vs MMR+V ‐ by brand ‐ from 0 to 42 days after vaccination… (low certainty).
1 finding from 1 review
Intervention not reported
MMRV vs MMR+V ‐ by brand ‐ from 7 to 10 days after vaccination (Priorix‐Tetra) · children 9 months to 15 years old
The intervention showed no clear difference in MMRV vs MMR+V ‐ by brand ‐ from 7 to 10 days after vaccination… (low certainty).
1 finding from 1 review
Intervention not reported
MMRV vs MMR+V ‐ by brand ‐ from 0 to 42 days after vaccination (ProQuad) · children 9 months to 15 years old
The intervention may leads to higher MMRV vs MMR+V ‐ by brand ‐ from 0 to 42 days after vaccination… (low certainty).
1 finding from 1 review
Intervention not reported
MMRV vs MMR+V ‐ by brand ‐ from 7 to 10 days after vaccination (ProQuad) · children 9 months to 15 years old
The intervention may leads to higher MMRV vs MMR+V ‐ by brand ‐ from 7 to 10 days after vaccination… (low certainty).
1 finding from 1 review
Intervention not reported
MMRV vs MMR ‐ by brand ‐ from 0 to 42 days after vaccination (Priorix‐Tetra) · children 9 months to 15 years old
The intervention showed no clear difference in MMRV vs MMR ‐ by brand ‐ from 0 to 42 days after vaccination… (low certainty).
1 finding from 1 review
Intervention not reported
MMRV vs MMR ‐ by brand ‐ from 7 to 10 days after vaccination (Priorix‐Tetra) · children 9 months to 15 years old
The intervention may leads to higher MMRV vs MMR ‐ by brand ‐ from 7 to 10 days after vaccination… (low certainty).
1 finding from 1 review
Intervention not reported
MMRV vs MMR ‐ by brand ‐ from 0 to 42 days after vaccination (ProQuad) · children 9 months to 15 years old
The intervention may leads to higher MMRV vs MMR ‐ by brand ‐ from 0 to 42 days after vaccination (ProQuad) (low certainty).
1 finding from 1 review
Intervention not reported
MMRV vs MMR ‐ by brand ‐ from 7 to 10 days after vaccination (ProQuad) · children 9 months to 15 years old
The intervention may leads to higher MMRV vs MMR ‐ by brand ‐ from 7 to 10 days after vaccination (ProQuad) (low certainty).
1 finding from 1 review
Intervention not reported
Self‐controlled case series (hospitalisations) ‐ hospitalisations ‐ risk period: 0 to 60 days · children 9 months to 15 years old
The intervention showed no clear difference in self‐controlled case series (hospitalisations) ‐ hospitalisations ‐… (low certainty).
1 finding from 1 review
Intervention not reported
Self‐controlled case series (GP visits) ‐ GP visit ‐ risk period: 0 to 5 days · children 9 months to 15 years old
The intervention may leads to higher self‐controlled case series (GP visits) ‐ GP visit ‐ risk period: 0… (low certainty).
1 finding from 1 review
Intervention not reported
Self‐controlled case series (GP visits) ‐ GP visit ‐ risk period: 6 to 60 days · children 9 months to 15 years old
The intervention showed no clear difference in self‐controlled case series (GP visits) ‐ GP visit ‐ risk period: 6… (low certainty).
1 finding from 1 review
Intervention not reported
Self‐controlled case series ‐ lobar pneumonia ‐ lobar pneumonia risk period (0 to 90 days) · children 9 months to 15 years old
The intervention may leads to lower self‐controlled case series ‐ lobar pneumonia ‐ lobar pneumonia risk… (low certainty).
1 finding from 1 review
Intervention not reported
Self‐controlled case series ‐ invasive bacterial infections ‐ invasive bacterial infections risk period (0 to 90 days) · children 9 months to 15 years old
The intervention showed no clear difference in self‐controlled case series ‐ invasive bacterial infections ‐… (low certainty).
1 finding from 1 review
Total failure: day 28 (PCR‐adjusted) · children and adults
Atovaquone‐proguanil showed no clear difference in total failure day 28 PCR‐adjusted compared with artemether‐lumefantrine (low certainty).
1 finding from 1 review